Immuno- and genetic therapy in autoimmune diseases

被引:10
作者
Chernajovsky, Y
Dreja, H
Daly, G
Annenkov, A
Gould, D
Adams, G
Croxford, JL
Baker, D
Podhajcer, OL
Mageed, RA
机构
[1] Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Bone & Joint Res Unit, London EC1M 6BQ, England
[2] UCL, Inst Neurol, Dept Neurochem, Neuroinflammat Grp, London WC1N 1PJ, England
[3] Kennedy Inst, London W6 8LH, England
[4] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar, RA-1053 Buenos Aires, DF, Argentina
基金
英国惠康基金;
关键词
gene therapy; diabetes; multiple sclerosis; rheumatoid arthritis; systemic lupus erythematosus;
D O I
10.1038/sj.gene.6363683
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Animal models of autoimmune disease have been developed that mimic some aspects of the pathophysiology of human disease. These models have increased our understanding of possible mechanisms of pathogenesis at the molecular and cellular level and have been important in the testing development and validation of new immunotherapies. The susceptibility to develop disease in the majority of these models is polygenic as is the case in humans. The exceptions to this rule are gene knock outs and transgenic models of particular genes which, in particular genetic backgrounds, have also contributed to the understanding of single gene function and their possible contribution to pathogenesis. Gene therapy approaches that target immune functions are being developed with encouraging results, despite the polygenic nature of these diseases. Basically this novel immuno-genetic therapy harnesses the knowledge of immunology with the myriad of biotechnological breakthroughs in vector design and delivery. Autoimmune disease is the result of genetic dysregulation which could be controlled by gene therapy. Here we summarize the genetic basis of these human diseases as well as some of the best characterized murine models. We discuss the strategies for their treatment using immuno- and gene therapy.
引用
收藏
页码:295 / 307
页数:13
相关论文
共 221 条
[1]   Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients [J].
Aebischer, P ;
Schluep, M ;
Deglon, N ;
Joseph, JM ;
Hirt, L ;
Heyd, B ;
Goddard, M ;
Hammang, JP ;
Zurn, AD ;
Kato, AC ;
Regli, F ;
Baetge, EE .
NATURE MEDICINE, 1996, 2 (06) :696-699
[2]  
AL-SABBAGH A, 1992, Neurology, V42, P346
[3]   A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling [J].
Alexopoulou, L ;
Pasparakis, M ;
Kollias, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) :2588-2592
[4]   ANALYSIS OF T-CELL FUNCTION IN AUTOIMMUNE MURINE STRAINS - DEFECTS IN PRODUCTION OF AND RESPONSIVENESS TO INTERLEUKIN-2 [J].
ALTMAN, A ;
THEOFILOPOULOS, AN ;
WEINER, R ;
KATZ, DH ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (03) :791-808
[5]  
Anderton SM, 1998, CIBA F SYMP, V215, P120
[6]  
ANDO DG, 1987, J IMMUNOL, V138, P3185
[7]   SPONTANEOUS MURINE LUPUS-LIKE SYNDROMES - CLINICAL AND IMMUNOPATHOLOGICAL MANIFESTATIONS IN SEVERAL STRAINS [J].
ANDREWS, BS ;
EISENBERG, RA ;
THEOFILOPOULOS, AN ;
IZUI, S ;
WILSON, CB ;
MCCONAHEY, PJ ;
MURPHY, ED ;
ROTHS, JB ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (05) :1198-1215
[8]  
ANNENKOV A, 2000, IN PRESS GENE THERAP
[9]  
Annenkov AE, 1998, J IMMUNOL, V161, P6604
[10]   CONTROL OF ESTABLISHED EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY INHIBITION OF TUMOR-NECROSIS-FACTOR (TNF) ACTIVITY WITHIN THE CENTRAL-NERVOUS-SYSTEM USING MONOCLONAL-ANTIBODIES AND TNF RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS [J].
BAKER, D ;
BUTLER, D ;
SCALLON, BJ ;
ONEILL, JK ;
TURK, JL ;
FELDMANN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :2040-2048